Niowave will expand its agreement to supply Actinium-225, a highly promising medical isotope, to AstraZeneca 10-year supply agreement will help advance new radioconjugateNiowave will expand its agreement to supply Actinium-225, a highly promising medical isotope, to AstraZeneca 10-year supply agreement will help advance new radioconjugate

Niowave Expands Global Supply Agreement with AstraZeneca to Deliver Actinium-225 for Next-Generation Cancer Therapies

  • Niowave will expand its agreement to supply Actinium-225, a highly promising medical isotope, to AstraZeneca
  • 10-year supply agreement will help advance new radioconjugate therapies capable of precisely targeting and destroying cancer cells

LANSING, Mich., Dec. 18, 2025 /PRNewswire/ — Niowave Inc., a U.S.- based global leader in medical radioisotope production, today announced the expansion of its existing supply agreement with AstraZeneca, a global biopharmaceutical company, to a 10-year commitment to deliver Actinium-225 (Ac-225), following AstraZeneca’s decision to exercise its option to increase capacity. The agreement secures a reliable and scalable supply of this critical isotope to advance AstraZeneca’s growing portfolio of radioconjugates (RCs). RCs are a type of cancer treatment that use radioactive particles to target and destroy cancer cells.

“Our expanded agreement with AstraZeneca underscores Niowave’s central role in scaling high-quality production of medical radioisotopes for the development of targeted cancer treatments,” said Mike Zamiara, CEO of Niowave. “We are pleased to play a role in ensuring that AstraZeneca’s promising pipeline of radioconjugates have the isotope supply they need.”

Ac-225 is one of the most promising radioisotopes in oncology as its emitted alpha particles deliver highly potent, DNA-damaging energy, enabling precise destruction of tumor cells while limiting harm to surrounding healthy tissue with targeted modalities like RCs. Despite its potential, global supply of Ac-225 remains limited. Niowave’s proprietary superconducting linear accelerator technology and radiochemistry provide sustainable, U.S.-based production to address this need.

As AstraZeneca advances RCs for prostate and other difficult-to-treat cancers, the agreement highlights the critical importance of securing dependable isotope supply.

About Niowave
Founded in 2005, Niowave, Inc. is a global leader in developing and operating superconducting electron linear accelerators and advancing radiochemistry procedures for medical isotope production. Headquartered in Lansing, Michigan, the company produces Ac-225 and other isotopes to support the next generation of cancer treatments, with a mission to accelerate the fight against cancer through reliable, scalable supply.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/niowave-expands-global-supply-agreement-with-astrazeneca-to-deliver-actinium-225-for-next-generation-cancer-therapies-302646279.html

SOURCE Niowave Inc.

Market Opportunity
WorldAssets Logo
WorldAssets Price(INC)
$0.5844
$0.5844$0.5844
+1.00%
USD
WorldAssets (INC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Bitcoin Has Taken Gold’s Role In Today’s World, Eric Trump Says

Bitcoin Has Taken Gold’s Role In Today’s World, Eric Trump Says

Eric Trump on Tuesday described Bitcoin as a “modern-day gold,” calling it a liquid store of value that can act as a hedge to real estate and other assets. Related Reading: XRP’s Biggest Rally Yet? Analyst Projects $20+ In October 2025 According to reports, the remark came during a TV appearance on CNBC’s Squawk Box, tied to the launch of American Bitcoin, the mining and treasury firm he helped start. Company Holdings And Strategy Based on public filings and company summaries, American Bitcoin has accumulated 2,443 BTC on its balance sheet. That stash has been valued in the low hundreds of millions of dollars at recent spot prices. The firm mixes large-scale mining with the goal of holding Bitcoin as a strategic reserve, which it says will help it grow both production and asset holdings over time. Eric Trump’s comments were direct. He told viewers that institutions are treating Bitcoin more like a store of value than a fringe idea, and he warned firms that resist blockchain adoption. The tone was strong at times, and the line about Bitcoin being a modern equivalent of gold was used to frame American Bitcoin’s role as both miner and holder.   Eric Trump has said: bitcoin is modern-day gold — unusual_whales (@unusual_whales) September 16, 2025 How The Company Went Public American Bitcoin moved toward a public listing via an all-stock merger with Gryphon Digital Mining earlier this year, a deal that kept most of the original shareholders in control and positioned the new entity for a Nasdaq debut. Reports show that mining partner Hut 8 holds a large ownership stake, leaving the Trump family and other backers with a minority share. The listing brought fresh attention and capital to the firm as it began trading under the ticker ABTC. Market watchers say the firm’s public debut highlights two trends: mining companies are trying to grow by both producing and holding Bitcoin, and political ties are bringing more headlines to crypto firms. Some analysts point out that holding large amounts of Bitcoin on the balance sheet exposes a company to price swings, while supporters argue it aligns incentives between miners and investors. Related Reading: Ethereum Bulls Target $8,500 With Big Money Backing The Move – Details Reaction And Possible Risks Based on coverage of the launch, investors have reacted with both enthusiasm and caution. Supporters praise the prospect of a US-based miner that aims to be transparent and aggressive about building a reserve. Critics point to governance questions, possible conflicts tied to high-profile backers, and the usual risks of a volatile asset being held on corporate balance sheets. Eric Trump’s remark that Bitcoin has taken gold’s role in today’s world reflects both his belief in its value and American Bitcoin’s strategy of mining and holding. Whether that view sticks will depend on how investors and institutions respond in the months ahead. Featured image from Meta, chart from TradingView
Share
NewsBTC2025/09/18 06:00
Tether CEO: AI Bubble Poses Biggest Risk to Bitcoin in 2026

Tether CEO: AI Bubble Poses Biggest Risk to Bitcoin in 2026

Tether CEO Paolo Ardoino has identified a potential AI-driven bubble as Bitcoin's biggest risk heading into 2026. However, he does not anticipate the same sharp corrections seen in previous market cycles, citing growing institutional adoption as a stabilizing force.
Share
MEXC NEWS2025/12/19 16:05
Bearish Sentiment Spikes as Bitcoin Drops to $84.8K, Creating Potential Contrarian Signal

Bearish Sentiment Spikes as Bitcoin Drops to $84.8K, Creating Potential Contrarian Signal

Bearish sentiment is surging across social media platforms following Bitcoin's pullback to $84,800, according to blockchain analytics firm Santiment. Retail investors are pushing fearful narratives harder than bullish outlooks, creating a notable shift in market mood.
Share
MEXC NEWS2025/12/19 15:56